Opicapone

Summary

Opicapone (CHEMBL1089318) is an approved small molecule (ATC N04BX04) targeting COMT; indicated across 1 condition including parkinson disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N04BX04
• Targets: 1 (COMT)
• Indications: 1 condition
• Clinical trials: 42
• Chemistry: 413.2 Da · C15H10Cl2N4O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1089318
Name	Opicapone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	135565903
ATC	N04BX04
Molecular formula	C15H10Cl2N4O6
Molecular weight	413.2
InChIKey	ASOADIZOVZTJSR-UHFFFAOYSA-N

SMILES: CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]

IUPAC name: 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol

Also known as: BIA-91067, Ongentys, Ontilyv, Opicapona, Opicapone, OPICAPONE, opicapone

Patent coverage: 252 distinct patent families (648 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 495 (76%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
COMT	Catechol-O-methyltransferase	Inhibition	9	2.1%	P21964

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Catechol O-methyltransferase, Catechol O-methyltransferase, Catechol O-methyltransferase.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
COMT	9	Ki	1	nM	CHEMBL_ACT_14722835
O88587	8.82	Ki	1.5	nM	CHEMBL_ACT_14722852
P22734	8.82	Ki	1.5	nM	CHEMBL_ACT_14722854
COMT	8	Ki	10	nM	CHEMBL_ACT_14722856
O88587	7.8	Ki	15.85	nM	CHEMBL_ACT_14722861
P22734	7.8	Ki	15.85	nM	CHEMBL_ACT_14722863

Target pathways

Aggregated over 1 target gene(s): COMT.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Methylation	1	COMT
Enzymatic degradation of dopamine by COMT	1	COMT
Enzymatic degradation of Dopamine by monoamine oxidase	1	COMT
Potential therapeutics for SARS	1	COMT

Dominant GO biological processes

GO term	Targets
behavioral fear response	1
response to hypoxia	1
synaptic transmission, dopaminergic	1
startle response	1
response to amphetamine	1
renin secretion into blood stream	1
glycogen metabolic process	1
prostaglandin metabolic process	1
response to oxidative stress	1
memory	1
visual learning	1
response to xenobiotic stimulus	1
response to wounding	1
response to toxic substance	1
gene expression	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	4	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE1	27
PHASE4	5
PHASE3	4
Not specified	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02847442	PHASE4	COMPLETED	Efficacy and Safety of Opicapone in Clinical Practice
NCT04821687	PHASE4	COMPLETED	A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
NCT04986982	PHASE4	COMPLETED	OpiCapone Effect on Motor Fluctuations and pAiN
NCT04986995	PHASE4	COMPLETED	OpicApone Sleep dISorder
NCT04990284	PHASE4	COMPLETED	eArly levoDopa With Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs.
NCT01227655	PHASE3	COMPLETED	Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients.
NCT01568073	PHASE3	COMPLETED	Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients With Wearing-off Phenomenon
NCT01851850	PHASE3	COMPLETED	Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
NCT04978597	PHASE3	COMPLETED	Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
NCT01568034	PHASE2	COMPLETED	A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
NCT01568047	PHASE2	COMPLETED	Multicentre Study in Four Parallel Groups of Parkinson’s Disease (PD) Patients
NCT01515891	PHASE1	COMPLETED	Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
NCT01520727	PHASE1	COMPLETED	A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
NCT01520987	PHASE1	COMPLETED	Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
NCT01532115	PHASE1	COMPLETED	Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
NCT01532128	PHASE1	COMPLETED	Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
NCT01532141	PHASE1	COMPLETED	Effect of Rasagiline on BIA 9-1067 Pharmacokinetics
NCT01533077	PHASE1	COMPLETED	Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
NCT01533116	PHASE1	COMPLETED	Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
NCT01536366	PHASE1	COMPLETED	Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
NCT02071810	PHASE1	COMPLETED	Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
NCT02071823	PHASE1	COMPLETED	Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
NCT02092168	PHASE1	COMPLETED	Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects
NCT02101190	PHASE1	COMPLETED	Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
NCT02169440	PHASE1	COMPLETED	Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
NCT02169453	PHASE1	COMPLETED	Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
NCT02169466	PHASE1	COMPLETED	Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
NCT02169479	PHASE1	COMPLETED	Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
NCT02169895	PHASE1	COMPLETED	Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
NCT02170376	PHASE1	COMPLETED	The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
NCT02305017	PHASE1	COMPLETED	Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers
NCT02305030	PHASE1	COMPLETED	Effect of Opicapone at Steady State on Warfarin Pharmacokinetics
NCT02305329	PHASE1	COMPLETED	Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
NCT03116295	PHASE1	COMPLETED	Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone
NCT03116308	PHASE1	COMPLETED	Effect of Food on Opicapone
NCT03496870	PHASE1	COMPLETED	A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson’s Disease Taking Levodopa.
NCT03820037	PHASE1	COMPLETED	Relative Bioavailability and Bioequivalence of Opicapone
NCT04265027	PHASE1	COMPLETED	Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)
NCT07403799	Not specified	RECRUITING	REal-life ON PARKinson’s - ITaly (REONPARK-IT)
NCT03959540	Not specified	COMPLETED	Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

15 molecules share ≥1 primary target. Top 15 by shared-target count:

Molecule	Source	Status	Shared targets
ENTACAPONE	ChEMBL	Phase 4 (approved)	COMT
TOLCAPONE	ChEMBL	Phase 4 (approved)	COMT
Afatinib	PubChem	Approved	COMT
alfaxalone	PubChem	Approved	COMT
Apixaban	PubChem	Approved	COMT
Binimetinib	PubChem	Approved	COMT
Diacetyl benzoyl lathyrol	PubChem	Approved	COMT
Edoxaban	PubChem	Approved	COMT
Fulvestrant	PubChem	Approved	COMT
Imipenem	PubChem	Approved	COMT
Linagliptin	PubChem	Approved	COMT
Pazopanib	PubChem	Approved	COMT
Pimavanserin	PubChem	Approved	COMT
Pyrazinamide	PubChem	Approved	COMT
Selumetinib	PubChem	Approved	COMT